Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | PKM | P14618 | 3/20 | 0.55 |
| ▸ | HTR6 | P50406 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 5/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | PKLR | P30613 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.48 |
| ▸ | BRD4 | O60885 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4559551 | 0.77 | HPGD (0.47) | HPGDPKMHTR6LMNAKMT2A | |
| SCHEMBL9968015 | 0.75 | HPGD (1.00) | HPGDPKMLMNAKMT2AMAPT | |
| SCHEMBL16976374 | 0.74 | MAOB (0.50) | HPGDKMT2ASMN1; SMN2BRD4MAPT | |
| SCHEMBL3898623 | 0.73 | HTR6 (0.56) | HPGDPKMHTR6LMNAKMT2A | |
| SCHEMBL11485190 | 0.72 | MAPT (0.71) | HPGDPKMHTR6LMNAKMT2A | |
| SCHEMBL8795432 | 0.71 | GRM5 (0.50) | HPGDLMNAKMT2ASMN1; SMN2MAPT | |
| SCHEMBL1344534 | 0.71 | MAOB (0.51) | HPGDSMN1; SMN2ALDH1A1 | |
| SCHEMBL13865315 | 0.70 | GRM5 (0.41) | HPGDPKMSMN1; SMN2ALDH1A1 | |
| SCHEMBL3357543 | 0.70 | HPGD (0.54) | HPGDPKMHTR6LMNAKMT2A | |
| SCHEMBL6304712 | 0.70 | MAOB (0.45) | HPGDPKMPKLRSMN1; SMN2BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7534801-B2 | Piperidinylchromen-6-ylsulfonamide compounds as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2009-05-19 | — | — | US | disclosed |
| US-7534801-B2 | Piperidinylchromen-6-ylsulfonamide compounds as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2009-05-19 | — | — | US | disclosed |
| US-20050107431-A1 | Piperidinylchromen-6-ylsulfonamide compounds as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2005-05-19 | — | — | US | disclosed |
| WO-2005037830-A1 | PIPERIDINYLCHROMEN-6-YLSULFONAMIDE COMPOUNDS AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH (US) | 2005-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107431-A1 | Piperidinylchromen-6-ylsulfonamide compounds as 5-hydroxytryptamine-6 ligands | HTR6, HTR5A, TPH1 | HPGD 1923/4885PKM 1845/4885HTR6 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.